-+ 0.00%
-+ 0.00%
-+ 0.00%

Lyell Immunopharma presents Phase 1/2 safety, translational data for ronde-cel in relapsed/refractory large B-cell lymphoma at EHA 2026

PUBT·06/04/2026 20:06:49
Listen to the news
Lyell Immunopharma presents Phase 1/2 safety, translational data for ronde-cel in relapsed/refractory large B-cell lymphoma at EHA 2026
  • Lyell Immunopharma flagged upcoming Phase 1/2 safety and translational updates for ronde-cel in relapsed or refractory large B-cell lymphoma at EHA 2026.
  • Results will be presented June 12 in Stockholm, with a focus on low-grade safety signals and translational work tied to durability of responses.
  • Ronde-cel remains in pivotal development, with updated PiNACLE data expected in the second half of 2026.
  • The company is targeting pivotal data by mid-2027, positioning a BLA submission in 2027.
  • A separate Phase 3 PiNACLE-H2H study is testing ronde-cel in second-line use against investigator’s choice of approved CAR-T options.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606041605PRIMZONEFULLFEED9732088) on June 04, 2026, and is solely responsible for the information contained therein.